News & Events
2025-12-29
Pamplona Therapeutics Receives FDA Clearance of IND Application for First-in-Class IRAK4 Degrader
Pamplona Therapeutics today announced that its first-in-class targeted protein degrader for the treatment of autoimmune diseases has received clearance from the U.S. Food and Drug Administration (FDA).
Learn more
-
Latest news
29 Dec 2025
Pamplona Therapeutics Receives FDA Clearance of IND Application for First-in-Class IRAK4 DegraderPamplona Therapeutics today announced that its first-in-class targeted protein degrader for the treatment of autoimmune diseases has received clearance from the U.S. Food and Drug Administration (FDA).
-
Latest news
29 Dec 2025
潘普洛纳生物First-in-Class降解剂分子获美国FDA临床试验默示许可 -
Latest news
12 Sep 2025
数百家角逐，仅 6 家入选——潘普洛纳闪耀国际舞台 -
Latest news
08 Sep 2025
喜报 | 潘普洛纳生物成功获得合成生物企业认定 -
Latest news
01 Sep 2025
捷报 | 潘普洛纳生物荣获光明区创新创业大赛二等奖
Address :
Email :
8/F, Building 1B, Weiguang Life
Science Park, Guangming District,
Shenzhen, Guangdong, China
info@pamplonatx.com
Follow us：
Follow us：
© 2025 Pamplona Therapeutics. All rights reserved.
© 2025 Pamplona Therapeutics.
All rights reserved.
All rights reserved.
